利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

68 条记录 (耗时 0.017 秒)

    METHOD OF PREDICTING RESPONSIVENESS OF A GASTROINTESTINAL CANCER PATIENT TO A CHEMOTHERAPY TREATMENT
    25.
    发明申请
    METHOD OF PREDICTING RESPONSIVENESS OF A GASTROINTESTINAL CANCER PATIENT TO A CHEMOTHERAPY TREATMENT 审中-公开

    公开(公告)号：WO2020104598A1

    公开(公告)日：2020-05-28

    申请号：PCT/EP2019/082110

    申请日：2019-11-21

    申请人： STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

    发明人： OOFT, Salo Noël ,  VOEST, Emile Eugene

    IPC分类号： G01N33/50 ,  G01N33/574

    摘要： Provided are methods for predicting the responsiveness (predictive assays) of a gastrointestinal cancer patient or stratifying said patient into a responder or non-responder to a chemotherapy treatment comprising: 1) 5-flurouracil or capecitabine in combination with irinotecan or 2) irinotecan only or 3) 5-fluorouracil alone. Also provided are methods of treating a gastrointestinal cancer patient using the predictive assay of the invention. The methods of the invention can be advantageously used to decide on or assign the best treatment option(s) to a gastrointestinal cancer patient, to prevent exposing said patient to the unnecessary side effects associated with a treatment which will prove to be ineffective at a later stage, and/or to reduce the financial burden associated with ineffective cancer treatment options.

    GENE SIGNATURES AND METHOD FOR PREDICTING RESPONSE TO PD-1 ANTAGONISTS AND CTLA-4 ANTAGONISTS, AND COMBINATION THEREOF
    26.
    发明申请
    GENE SIGNATURES AND METHOD FOR PREDICTING RESPONSE TO PD-1 ANTAGONISTS AND CTLA-4 ANTAGONISTS, AND COMBINATION THEREOF 审中-公开

    公开(公告)号：WO2020005068A3

    公开(公告)日：2020-01-02

    申请号：PCT/NL2019/050401

    申请日：2019-06-28

    申请人： STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

    发明人： KRIJGSMAN, Oscar ,  PEEPER, Daniel Simon

    IPC分类号： C12Q1/6886

    摘要： The present invention relates to the field of cancer, more particularly to the field of immunotherapy and gene signatures. Provided are two specific and distinct gene signatures, namely a Response Immune Signal (RIS) gene signature and a Stromal Immune Signal (SIS) gene signature, which can be used as biomarkers to accurately predict the response of a cancer subject to treatment with a PD-1 antagonist (e.g., PD-1 antibody) and/or a CTLA-4 antagonist (e.g., CTLA-4 antibody). In particular, it was found that the RIS and SIS gene signatures of the invention may be used in combination to predict the response of a cancer subject to treatment with a combination therapy consisting of a PD-1 antagonist (e.g., PD-1 antibody) and a CTLA-4 antagonist (e.g., CTLA-4 antibody). The gene signatures of the invention may be advantageously used in methods for treating cancer, such as melanoma, and to help devise treatment strategies best suited to individual patients (e.g., to achieve personalized therapy, and spare patients from undesired side effects, e.g., toxicity).

    GENE SIGNATURES AND METHOD FOR PREDICTING RESPONSE TO PD-1 ANTAGONISTS AND CTLA-4 ANTAGONISTS, AND COMBINATION THEREOF
    27.
    发明申请
    GENE SIGNATURES AND METHOD FOR PREDICTING RESPONSE TO PD-1 ANTAGONISTS AND CTLA-4 ANTAGONISTS, AND COMBINATION THEREOF 审中-公开

    公开(公告)号：WO2020005068A2

    公开(公告)日：2020-01-02

    申请号：PCT/NL2019/050401

    申请日：2019-06-28

    申请人： STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

    发明人： KRIGJGSMAN, Oscar ,  PEEPER, Daniel Simon

    IPC分类号： C12Q1/6886

    摘要： The present invention relates to the field of cancer, more particularly to the field of immunotherapy and gene signatures. Provided are two specific and distinct gene signatures, namely a Response Immune Signal (RIS) gene signature and a Stromal Immune Signal (SIS) gene signature, which can be used as biomarkers to accurately predict the response of a cancer subject to treatment with a PD-1 antagonist (e.g., PD-1 antibody) and/or a CTLA-4 antagonist (e.g., CTLA-4 antibody). In particular, it was found that the RIS and SIS gene signatures of the invention may be used in combination to predict the response of a cancer subject to treatment with a combination therapy consisting of a PD-1 antagonist (e.g., PD-1 antibody) and a CTLA-4 antagonist (e.g., CTLA-4 antibody). The gene signatures of the invention may be advantageously used in methods for treating cancer, such as melanoma, and to help devise treatment strategies best suited to individual patients (e.g., to achieve personalized therapy, and spare patients from undesired side effects, e.g., toxicity).

    METHODS FOR PREDICTING TREATMENT OUTCOME AND/OR FOR SELECTING A SUBJECT SUITABLE FOR IMMUNE CHECKPOINT THERAPY
    28.
    发明申请
    METHODS FOR PREDICTING TREATMENT OUTCOME AND/OR FOR SELECTING A SUBJECT SUITABLE FOR IMMUNE CHECKPOINT THERAPY 审中-公开

    公开(公告)号：WO2019156568A8

    公开(公告)日：2019-08-15

    申请号：PCT/NL2019/050092

    申请日：2019-02-12

    申请人： STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS ,  UNIVERSITÄT BASEL

    发明人： SCHUMACHER, Antonius Nicolaas Maria ,  ZIPPELIUS, Alfred Karl Josef ,  THOMMEN, Daniela Stefanie ,  KÖLZER, Viktor Hendrik ,  MERTZ, Kirsten Diana

    IPC分类号： G01N33/574

    摘要： The present invention relates to the field of biomarker development for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds. Provided are assays for quantifying PD-1 expression (i.e. immunostaining intensity) in cells present in a tumor sample (i.e. intratumoral cells), which are advantageously used to identify a unique sub-population of intratumoral cells referred to herein as PD-1 T cells, which serves as a biomarker for cancer immunotherapy with PD-1 inhibitor compounds and/or PD-L1 inhibitor compounds alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab). The present invention also provides methods of selecting a human subject diagnosed with cancer (e.g. non-small cell lung cancer (NSCLC)) suitable for immune checkpoint therapy with agents such as PD-1 inhibitors (e.g. nivolumab) and/or PD-L1 inhibitors (e.g. atezolizumab) alone or in combination with other therapeutic agents (e.g. CTLA- 4 inhibitor compound, e.g. ipilimumab), methods for predicting responsiveness to immune checkpoint therapy with agents such as PD-1 inhibitors and/or PD-L1 inhibitors, and method of treatment of a human subject diagnosed with cancer using PD-1 inhibitors and/or PD-L1 inhibitors alone or in combination with other therapeutic agents (e.g. CTLA-4 inhibitor compound, e.g. ipilimumab).